Brief: Landos Biopharma Provides Business Update And Reports First Quarter 2023 Results
12/05/2023 13:39
Landos Biopharma Inc LABP.O :
* LANDOS BIOPHARMA PROVIDES BUSINESS UPDATE AND REPORTS
FIRST
QUARTER 2023 RESULTS
* LANDOS BIOPHARMA INC - NEXUS PHASE 2 CLINICAL TRIAL OF
NX-13 FOR
ULCERATIVE COLITIS INITIATED
* LANDOS BIOPHARMA INC - NEXUS TOP-LINE RESULTS PLANNED FOR
Q4
2024
* LANDOS BIOPHARMA INC - SUFFICIENT CASH TO FUND PLANNED
OPERATIONS INTO FIRST HALF OF 2025
* LANDOS BIOPHARMA INC- QTRLY LOSS PER SHARE $0.09
Source text for Eikon: ID:nGNX3zvKKd
Further company coverage: LABP.O
Recent news on Landos Biopharma
See all newsLandos Biopharma Inc expected to post a loss of 100 cents a share - Earnings Preview
Deals of the day-Mergers and acquisitions
U.S. STOCKS ON THE MOVE-Super Micro, Micron Technology, Navios Maritime
U.S. STOCKS ON THE MOVE-Landos Biopharma, Foot Locker, US energy sector
Brief: AbbVie To Acquire Landos Biopharma